| dbo:abstract
|
- Ponesimod ist ein Arzneistoff aus der Gruppe der Immunmodulatoren, der zur oralen Behandlung der multiplen Sklerose (MS) eingesetzt wird. (de)
- Le ponésimod est un modulateur des récepteurs à la sphingosine-1-phosphate de type 1 (S1PR1) et est en cours de test dans la sclérose en plaques et le psoriasis. (fr)
- Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis (MS). The most common side effects include upper respiratory tract infection, hepatic transaminase elevation, and hypertension. Ponesimod was approved for medical use in the United States in March 2021 and in the European Union in June 2021. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 13424 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:cl
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:eliminationHalfLife
| |
| dbp:excretion
| |
| dbp:h
| |
| dbp:image
|
- Ponesimod ball-and-stick model.png (en)
|
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:legalAu
| |
| dbp:legalCa
| |
| dbp:legalEu
| |
| dbp:legalUs
| |
| dbp:metabolism
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pregnancyAu
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:smiles
|
- CCC/N=C\1/NC3=CC=CC=C3C (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- LPAUOXUZGSBGDU-STDDISTJSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
| |
| dbp:unii
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dct:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Ponesimod ist ein Arzneistoff aus der Gruppe der Immunmodulatoren, der zur oralen Behandlung der multiplen Sklerose (MS) eingesetzt wird. (de)
- Le ponésimod est un modulateur des récepteurs à la sphingosine-1-phosphate de type 1 (S1PR1) et est en cours de test dans la sclérose en plaques et le psoriasis. (fr)
- Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis (MS). The most common side effects include upper respiratory tract infection, hepatic transaminase elevation, and hypertension. Ponesimod was approved for medical use in the United States in March 2021 and in the European Union in June 2021. (en)
|
| rdfs:label
|
- Ponesimod (de)
- Ponésimod (fr)
- Ponesimod (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
